University of Queensland
scientists say clinical trials for a
new dengue fever treatment could
start within 12 months, after they
identified similarities in how the
body reacts to dengue virus and
bacterial infections.
The dengue virus NS1 protein acts
as a toxin in the body in a similar
manner to the way bacterial cell
wall products lead to septic shock
in bacterial infections - meaning
existing drugs could possibly be repurposed
to treat dengue fever.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.